Therefore, we suggest that IDF-11774 represents a metabolic inhibitor suitable for use in cancer therapy to cure cancers containing mutations in KRAS, PTEN, EGFR T790M, p53, PI3K, and VHL, alone or in combination with other anticancer drugs or radiotherapy. This evidence concerns the gene EGFR and cancer.